- Policy
- Gov’t to fully investigate its COVID-19 research support
- by Lee, Tak-Sun Nov 1, 2022 06:02am
- The Ministry of Health and Welfare announced that it will conduct a full investigation on all of the projects it had supported for the clinical trial research of COVID-19 treatments and vaccines by the first quarter of next year. Since 2020, a total of 10 companies were selected for the government's COVID-19 treatment and vaccine clinical
- Policy
- It takes 218 days to register after applying for a new drug
- by Kim, Jung-Ju Oct 31, 2022 06:07am
- Among the new drugs introduced in Korea, drugs that started the payroll process from insurance application to registration last year took an average of 218 days. Among them, the treatment for rare diseases took 238 days and the anticancer drug took 227 days. Considering that the legal processing period is 7 months (210 days), the government emph
- InterView
- “BMS makes the next leap with its solid pipeline”
- by Eo, Yun-Ho Oct 31, 2022 06:06am
- Mergers have become one of the main survival strategies for global multinational pharmaceutical companies. In addition to buying new substances, companies are also making synergy, absorbing companies that own pipelines with high potential. BMS is one representative example of such successful mergers. When the power of its portfolio decli
- Company
- MET-targeted anticancer drug Tabrecta reattempts reimb
- by Eo, Yun-Ho Oct 31, 2022 06:06am
- Once again, the MET-targeted anticancer drug Tabrecta is attempting to receive insurance reimbursement in Korea. According to industry sources, Novartis Korea has recently started the reimbursement process for Tabrecta (capmatinib in Korea. As the agenda was unable to pass deliberation by the Health Insurance Review and Assessment Service
- Policy
- Koselugo & Retevmo's benefit registration can be shortened
- by Lee, Tak-Sun Oct 31, 2022 06:06am
- The registration of drug benefits such as Koselugo and Retevmo, which are currently under evaluation, is expected to be shortened by 30 days. This is because the NHIS and the HIRA have decided to shorten the benefit registration period for drugs used in life-threatening diseases. Koselugo and Retevmo are drugs licensed through the Ministry of
- Company
- Samsung Biologics surpassed ₩2 trillion in sales
- by Kim, Jin-Gu Oct 31, 2022 06:06am
- Samsung BioLogics surpassed 2 trillion won in cumulative sales in the third quarter. It exceeded 1.568 trillion won in annual sales last year in three quarters. On the 26th, Samsung BioLogics announced that it achieved 873 billion won in sales and 324.7 billion won in operating profit in the third quarter. Both sales and operating profit rose
- Company
- The commercialization of Camzyos is expected in Korea
- by Eo, Yun-Ho Oct 28, 2022 05:57am
- It is expected that the new HCM drug Camzyos will be commercialized in Korea. According to related industries, BMS Pharmaceutical Korea recently submitted an application to the Ministry of Food and Drug Safety for permission for the NYHA Class 2-3 (class II-III) HCM treatment Camzyos. Camzyos is acquired by BMS for $13.1 billion in 2020 and i
- Company
- Zerbaxa's benefit in 5 Years
- by Oct 28, 2022 05:57am
- After five years of domestic approval, the MSD super antibiotic "Zerbaxa (Ceftolozane/Tazobactam)" was registered. It is expected to help reduce the recent surge in carbapenem antibiotic resistance. MSD Korea held a press conference at the Koreana Hotel in Jung-gu, Seoul on the 27th to commemorate the registration of Zerbaxa, a multidrug-resi
- Opinion
- [Reporter’s View]Raising price of cold medicines not enough
- by Lee, Tak-Sun Oct 28, 2022 05:56am
- With the shortage of cold medicines remaining unresolved, the government proposed a drug price increase as its final card. The government decided to first take price adjustment applications for dispensed drugs that contain acetaminophen, which is cheaper than other cold medicines. The government had been implementing support measures
- Company
- AZ-Abbott to copromote diabetic kidney disease treatments
- by Eo, Yun-Ho Oct 28, 2022 05:56am
- On the 26th, AstraZeneca Korea announced that it had signed a joint promotion agreement with Abbott Korea for the early diagnosis and treatment of patients with diabetic kidney disease. The signing ceremony was held at AstraZeneca Korea’s headquarters in Samseong-dong, Seoul on the 25th ,in the presence of key officials from both compani
